proxyvotesnow.com

Home › Companies › BIOCRYST PHARMACEUTICALS INC. › 2023-2024

BIOCRYST PHARMACEUTICALS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings. Page generated 04 October 2026.

  • 7Reported items
  • 230Asset managers
  • 1,311Fund votes
  • 2024-06-12Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore BIOCRYST PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

How asset managers voted at the BIOCRYST PHARMACEUTICALS INC. 2023-2024 meeting

Each item below shows how the 230 asset managers that disclosed a BIOCRYST PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of BIOCRYST PHARMACEUTICALS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on an advisory basis, the Company's executive compensation.

SECTION 14A SAY-ON-PAY VOTES

Combines 8 wordings of this item as funds reported it.

99.6% fund support · no official result

FOR 99.5%

The 219 asset managers below cast 99.6% of the shares they voted on this item FOR (136,921,585 for, 527,464 against).

FOR: 136,921,585 (99.6%)AGAINST: 527,464 (0.4%)ABSTAIN: 27,957 (0.0%)NOT VOTED: 1,850 (0.0%)
Largest asset managers voting on “To approve, on an advisory basis, the Company's executive compensation.” at BIOCRYST PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
State Street25,465,7540 00For
Vanguard17,887,6140 00For
Avoro Capital Advisors LLC11,489,7570 00For
BlackRock10,929,9100 00For
BAKER BROS. ADVISORS LP10,075,3430 00For
Kynam Capital Management, LP6,863,7620 00For
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)4,995,0000 00For
Rock Springs Capital Management LP3,530,6800 00For
Charles Schwab3,478,5960 00For
BRAIDWELL LP3,119,5560 00For
GW&K Investment Management, LLC2,878,3200 00For
Nuveen2,635,5010 00For
TIAA2,627,1850 00For
Columbia Threadneedle1,976,3630 00For
1919 Investment Counsel, LLC1,837,8740 00For
Voya1,748,1910 00For
RICE HALL JAMES & ASSOCIATES, LLC1,550,3310 00For
ALKEON CAPITAL MANAGEMENT LLC1,481,1720 00For
Two Sigma1,387,0190 00For
Fisher Asset Management, LLC1,266,2550 00For
Direxion Shares ETF Trust1,198,8480 00For
Rafferty Asset Management, LLC1,198,8480 00For
Fidelity1,029,3030 00For
Northern Trust984,9720 00For
Putnam877,9510 00For

Showing the 25 largest of 219 asset managers. See all 219 in the interactive database.

2. To approve an amended and restated Stock Incentive Plan, increasing the number of shares available for issuance under the Stock Incentive Plan by 7,000,000 shares.

CORPORATE GOVERNANCE

Combines 4 wordings of this item as funds reported it.

70% fund support · no official result

FOR 70%AGAINST 30%

The 62 asset managers below cast 70% of the shares they voted on this item FOR (37,918,315 for, 16,596,478 against).

FOR: 37,918,315 (69.5%)AGAINST: 16,596,478 (30.4%)ABSTAIN: 30,957 (0.1%)
Largest asset managers voting on “To approve an amended and restated Stock Incentive Plan, increasing the number of shares available for issuanc” at BIOCRYST PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard17,392,7720 00For
State Street123,06711,199,298 00Against
Kynam Capital Management, LP6,863,7620 00For
BlackRock4,256,3730 00For
TIAA2,627,1850 00For
Columbia Threadneedle1,976,3630 00For
Charles Schwab1,739,2980 00For
Direxion Shares ETF Trust01,198,848 00Against
Fidelity814,3790 00For
AMG FUNDS0801,102 00Against
Voya0750,688 00Against
MUTUAL FUND SERIES TRUST675,0000 00For
Advantage Advisers Xanthus Fund, L.L.C.585,5730 00For
John Hancock0490,960 00Against
Equitable199,415233,800 00Against
Segall Bryant & Hamill Trust0330,506 00Against
ProShares0272,414 00Against
MoA Funds Corp0202,187 00Against
Lincoln Financial0159,603 00Against
First Trust0145,317 00Against
ALPS ETF Trust0129,879 00Against
Two Roads Shared Trust121,0920 00For
Goldman Sachs0111,569 00Against
CLEARWATER INVESTMENT TRUST99,9370 00For
AIG/SunAmerica093,415 00Against

Showing the 25 largest of 62 asset managers. See all 62 in the interactive database.

3. To ratify the selection of Ernst & Young LLP as the Company's independent registered public accountants for 2024.

AUDIT-RELATED

Combines 3 wordings of this item as funds reported it.

99.7% fund support · no official result

FOR 99.6%

The 60 asset managers below cast 99.7% of the shares they voted on this item FOR (47,531,543 for, 119,488 against).

FOR: 47,531,543 (99.7%)AGAINST: 119,488 (0.3%)ABSTAIN: 27,957 (0.1%)
Largest asset managers voting on “To ratify the selection of Ernst & Young LLP as the Company's independent registered public accountants for 20” at BIOCRYST PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard17,392,7720 00For
State Street11,302,81419,551 00For
BlackRock4,256,3730 00For
TIAA2,627,1850 00For
Columbia Threadneedle1,976,3630 00For
Charles Schwab1,739,2980 00For
Direxion Shares ETF Trust1,198,8480 00For
Fidelity814,3790 00For
AMG FUNDS801,1020 00For
Voya750,6880 00For
MUTUAL FUND SERIES TRUST675,0000 00For
Advantage Advisers Xanthus Fund, L.L.C.585,5730 00For
John Hancock490,9600 00For
Equitable433,2150 00For
Segall Bryant & Hamill Trust330,5060 00For
ProShares272,4140 00For
MoA Funds Corp202,1870 00For
Lincoln Financial159,6030 00For
First Trust145,3170 00For
ALPS ETF Trust129,8790 00For
Two Roads Shared Trust121,0920 00For
Goldman Sachs111,5690 00For
CLEARWATER INVESTMENT TRUST099,937 00Against
AIG/SunAmerica93,4150 00For
Global X84,5280 00For

Showing the 25 largest of 60 asset managers. See all 60 in the interactive database.

4. Election of Directors: A. Machelle Sanders

DIRECTOR ELECTIONS

Combines 3 wordings of this item as funds reported it.

100% fund support · no official result

FOR 99.3%

The 57 asset managers below cast 100% of the shares they voted on this item FOR (46,486,865 for, 0 against).

FOR: 46,486,865 (99.3%)ABSTAIN: 326,565 (0.7%)
Largest asset managers voting on “Election of Directors: A. Machelle Sanders” at BIOCRYST PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard17,392,7720 00For
State Street11,309,5950 12,7700For
BlackRock4,256,3730 00For
TIAA2,627,1850 00For
Columbia Threadneedle1,976,3630 00For
Charles Schwab1,739,2980 00For
Direxion Shares ETF Trust1,198,8480 00For
Fidelity814,3790 00For
AMG FUNDS801,1020 00For
Voya750,6880 00For
Advantage Advisers Xanthus Fund, L.L.C.585,5730 00For
John Hancock490,9600 00For
Equitable199,4150 233,8000Abstain
Segall Bryant & Hamill Trust330,5060 00For
ProShares272,4140 00For
MoA Funds Corp202,1870 00For
Lincoln Financial159,6030 00For
First Trust145,3170 00For
ALPS ETF Trust129,8790 00For
Goldman Sachs111,5690 00For
CLEARWATER INVESTMENT TRUST99,9370 00For
AIG/SunAmerica93,4150 00For
Global X84,5280 00For
MASTER INVESTMENT PORTFOLIO70,8020 00For
Pacific Life68,7490 00For

Showing the 25 largest of 57 asset managers. See all 57 in the interactive database.

5. Election of Directors: Nancy J. Hutson, Ph.D.

DIRECTOR ELECTIONS

Combines 3 wordings of this item as funds reported it.

100% fund support · no official result

FOR 75%ABSTAIN 25%

The 57 asset managers below cast 100% of the shares they voted on this item FOR (35,122,910 for, 0 against).

FOR: 35,122,910 (75.0%)ABSTAIN: 11,690,520 (25.0%)
Largest asset managers voting on “Election of Directors: Nancy J. Hutson, Ph.D.” at BIOCRYST PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard17,392,7720 00For
State Street241,8400 11,080,5250Abstain
BlackRock4,256,3730 00For
TIAA2,627,1850 00For
Columbia Threadneedle1,976,3630 00For
Charles Schwab1,739,2980 00For
Direxion Shares ETF Trust1,198,8480 00For
Fidelity814,3790 00For
AMG FUNDS801,1020 00For
Voya750,6880 00For
Advantage Advisers Xanthus Fund, L.L.C.585,5730 00For
John Hancock490,9600 00For
Equitable199,4150 233,8000Abstain
Segall Bryant & Hamill Trust330,5060 00For
ProShares272,4140 00For
MoA Funds Corp202,1870 00For
Lincoln Financial00 159,6030Abstain
First Trust145,3170 00For
ALPS ETF Trust129,8790 00For
Goldman Sachs111,5690 00For
CLEARWATER INVESTMENT TRUST00 99,9370Abstain
AIG/SunAmerica93,4150 00For
Global X84,5280 00For
MASTER INVESTMENT PORTFOLIO70,8020 00For
Pacific Life68,7490 00For

Showing the 25 largest of 57 asset managers. See all 57 in the interactive database.

6. Election of Directors: Vincent J. Milano

DIRECTOR ELECTIONS

Combines 3 wordings of this item as funds reported it.

100% fund support · no official result

FOR 99.4%

The 57 asset managers below cast 100% of the shares they voted on this item FOR (46,538,903 for, 0 against).

FOR: 46,538,903 (99.4%)ABSTAIN: 274,527 (0.6%)
Largest asset managers voting on “Election of Directors: Vincent J. Milano” at BIOCRYST PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard17,392,7720 00For
State Street11,309,5950 12,7700For
BlackRock4,256,3730 00For
TIAA2,627,1850 00For
Columbia Threadneedle1,976,3630 00For
Charles Schwab1,739,2980 00For
Direxion Shares ETF Trust1,198,8480 00For
Fidelity814,3790 00For
AMG FUNDS801,1020 00For
Voya750,6880 00For
Advantage Advisers Xanthus Fund, L.L.C.585,5730 00For
John Hancock490,9600 00For
Equitable199,4150 233,8000Abstain
Segall Bryant & Hamill Trust330,5060 00For
ProShares272,4140 00For
MoA Funds Corp202,1870 00For
Lincoln Financial159,6030 00For
First Trust145,3170 00For
ALPS ETF Trust129,8790 00For
Goldman Sachs111,5690 00For
CLEARWATER INVESTMENT TRUST99,9370 00For
AIG/SunAmerica93,4150 00For
Global X84,5280 00For
MASTER INVESTMENT PORTFOLIO70,8020 00For
Pacific Life68,7490 00For

Showing the 25 largest of 57 asset managers. See all 57 in the interactive database.

7. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTES

100% fund support · no official result

FOR 100%

The 3 asset managers below cast 100% of the shares they voted on this item FOR (1,461,757 for, 0 against).

FOR: 1,461,757 (100.0%)
Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at BIOCRYST PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Eversept Partners, LP1,438,1120 00For
ALGERT GLOBAL LLC13,5900 00For
JPMorgan10,0550 00For

Largest BIOCRYST PHARMACEUTICALS INC. shareholders voting in 2023-2024

Ranked by the number of BIOCRYST PHARMACEUTICALS INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 205,771,000 shares outstanding at the time of that meeting.

Top BIOCRYST PHARMACEUTICALS INC. shareholders by shares voted, 2023-2024
#Asset manager % of shares outstanding
1State Street 12.38%
2Vanguard 8.69%
3Avoro Capital Advisors LLC 5.58%
4BlackRock 5.31%
5BAKER BROS. ADVISORS LP 4.90%
6Kynam Capital Management, LP 3.34%
7DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 2.43%
8Rock Springs Capital Management LP 1.72%
9Charles Schwab 1.69%
10BRAIDWELL LP 1.52%

Reported BIOCRYST PHARMACEUTICALS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

BIOCRYST PHARMACEUTICALS INC. beneficial owners on record for the 2023-2024 proxy season
Holder % outstanding Disclosure
Vanguard Group 10.59% 13F
BlackRock 10.33% 13F
State Street 8.49% 13F
Avoro Capital Advisors LLC 6.34% DEF14A
Morgan Stanley 2.53% 13F
Jon P. Stonehouse 2.25% DEF14A
Geode Capital 2.14% 13F
Goldman Sachs 1.32% 13F
Nuveen 1.27% 13F
Millennium Management 0.99% 13F

Percentages above are of 205,771,000 shares outstanding, as reported by BIOCRYST PHARMACEUTICALS INC. on its Form 10-K dated 2023-12-31 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from BIOCRYST PHARMACEUTICALS INC.’s 10-K dated 2023-12-31. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At BIOCRYST PHARMACEUTICALS INC.'s shareholder meeting held 2024-06-12, in the 2023-2024 proxy season, 230 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,311 separate fund positions. Their filings are grouped here into 7 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. No official Form 8-K vote tally has been matched to this meeting, so this page states no certified outcome for its most widely held ballot item. On that item — To approve, on an advisory basis, the Company's executive compensation. — the reporting funds cast 99.6% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

BIOCRYST PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.